We invite you to read the report prepared by HTA Consulting, which aims to present systemic consequences related to the introduction of a new model of access to innovative drugs in Poland in the light of the Medical Fund Act.
Due to the Act on the Medical Fund in force we looked into registration drugs in European Medicines Agency (EMA) to see which products may be included in the upcoming high clinical value drugs list by AOTMiT. From 2017 to the end of July 2021, 268 new
We invite you to read the report "Innovations. Medical Fund." (PL only). The report aims to benefit from access systems to introduce a new model of access to other drugs in the light of the offensive to offer a medical mechanism.
NHF spending on medical products, foodstuffs and medical devices reimbursement from January till February 2021 amounted to PLN 2.09 billion, including PLN 1.37 billion expenditures on products from outpatients list, PLN 0.65 billion from drug programmes and PLN 0.07 billion from chemotherapy.NHF spending on TOP10